The JNK Inhibitor XG-102 Protects against TNBS-Induced Colitis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The c-Jun N-terminal kinase (JNK)-inhibiting peptide D-JNKI-1, syn. XG-102 was tested for its therapeutic potential in acute inflammatory bowel disease (IBD) in mice. Rectal instillation of the chemical irritant trinitrobenzene sulfonic acid (TNBS) provoked a dramatic acute inflammation in the colon of 7-9 weeks old mice. Coincident subcutaneous application of 100 µg/kg XG-102 significantly reduced the loss of body weight, rectal bleeding and diarrhoea. After 72 h, the end of the study, the colon was removed and immuno-histochemically analysed. XG-102 significantly reduced (i) pathological changes such as ulceration or crypt deformation, (ii) immune cell pathology such as infiltration and presence of CD3- and CD68-positive cells, (iii) the production of tumor necrosis factor (TNF)-α in colon tissue cultures from TNBS-treated mice, (iv) expression of Bim, Bax, FasL, p53, and activation of caspase 3, (v) complexation of JNK2 and Bim, and (vi) expression and activation of the JNK substrate and transcription factor c-Jun. A single application of subcutaneous XG-102 was at least as effective or even better depending on the outcome parameter as the daily oral application of sulfasalazine used for treatment of IBD.The successful and substantial reduction of the severe, TNBS-evoked intestinal damages and clinical symptoms render the JNK-inhibiting peptide XG-102 a powerful therapeutic principle of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593
Chemically induced mouse models of intestinal inflammation
Wirtz, S., Neufert, C., Weigmann, B., & Neurath, M. F. (2007) · Nature Protocols · doi:10.1038/nprot.2007.41 · Cited by 1,567
Bacterial flagellin is a dominant antigen in Crohn disease
Lodes, M. J., Cong, Y., Elson, C. O., Mohamath, R., Landers, C. J., Targan, S. R., Fort, M., & Hershberg, R. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420295 · Cited by 802 · cited 1×
“JNK activity, which is increased in IBD patients [9,10,11,12], sensitizes epithelial cells against bacterial components and cytokines [13,14].”
BackgroundA peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658
Targeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585 · cited 1×
“as well as atherosclerosis [32] (reviewed by [33,34,35]).”
BackgroundMitogen activated protein kinases: a role in inflammatory bowel disease?
Broom, O. J., Widjaya, B., Troelsen, J., Olsen, J., & Nielsen, O. H. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.04033.x · Cited by 177 · cited 2×
“The pathogenetic development of IBD is characterized by three causative areas such as (i) genetic susceptibility for mutations of proteins facilitating the access of microbes to the epithelium and underlying layers, (ii) luminal antigenic provocation from endogenous microbes or food allergens and (iii) environmental t…”
BackgroundA Peptide Inhibitor of c-Jun N-Terminal Kinase for the Treatment of Endotoxin-Induced Uveitis
Touchard, E., Omri, S., Naud, M.-C., Berdugo, M., Deloche, C., Abadie, C., Jonet, L., Jeanny, J.-C., Crisanti, P., de Kozak, Y., et al. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4733 · Cited by 43 · cited 2×
“matic hearing loss [36] and uveitis [37].”
BackgroundUnderstanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1
Yan, C., Kaoud, T., Lee, S., Dalby, K. N., & Ren, P. (2011) · The Journal of Physical Chemistry B · doi:10.1021/jp1073522 · Cited by 36
Cited by
JNK signalling in cancer: in need of new, smarter therapeutic targets
Bubici, C., & Papa, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12432 · Cited by 346
Chiquet, C., Aptel, F., Creuzot-Garcher, C., Berrod, J.-P., Kodjikian, L., Massin, P., Deloche, C., Perino, J., Kirwan, B.-A., de Brouwer, S., et al. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.10.012 · Cited by 52
Beydoun, T., Deloche, C., Perino, J., Kirwan, B.-A., Combette, J.-M., & Behar-Cohen, F. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0247 · Cited by 39
Deloche, C., Lopez‐Lazaro, L., Mouz, S., Perino, J., Abadie, C., & Combette, J. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.20 · Cited by 37
El Zaoui, I., Touchard, E., Berdugo, M., Abadie, C., Kowalczuk, L., Deloche, C., Zhao, M., Naud, M.-C., Combette, J.-M., & Behar-Cohen, F. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2014.0019 · Cited by 31
“Its specific inhibition by XG-102 blocks the phosphorylation of its nuclear target, cJun, which prevents the transcription of pro-inflammatory cytokines/chemokines and the activation of the harmful intracellular processes such as apoptosis.(12,18,19) In this study, we confirmed that XG-102 exerts anti-inflammatory eff…”
Metadata
- Authors
- Reinecke, K., Eminel, S., Dierck, F., Roessner, W., Kersting, S., Chromik, A. M., Gavrilova, O., Laukevicience, A., Leuschner, I., Waetzig, V., Rosenstiel, P., Herdegen, T., & Sina, C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-13
- Volume
- 7
- Issue
- 3
- Pages
- e30985
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2050206354
- Cited by
- 47
- References
- 9
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.